A collaboration among interventional oncologists pooling outcomes of 155 patients with neuroendocrine tumor liver metastases treated at seven cancer centers across the United States has won the CVIR Award for most highly cited article at the 2018 CIRSE Annual Meeting in Lisbon, Portugal. The scientific abstract had previously won a top poster prize at the 2016 CIRSE meeting. Pictured are co-authors Ghassan El-Haddad from Moffitt Cancer Center and Dan Sze from Stanford University accepting the award today at the CVIR Reception in Lisbon.
The article was written by James Chen, MD, then Chief Fellow in Interventional Radiology at the University of Pennsylvania. Senior author Michael Soulen, MD FSIR FCIRSE observed, "This shows the power of multi-institutional collaboration. Even though it was a retrospective study, by using a standardized database like a registry, we can generalize results across many centers on a large sample of patients. The results of this collaboration provided the basis for designing the RETNET trial (Randomized Embolization Trial for NeuroEndocrine Tumors, NCT02724540), the first randomized controlled trial of standard-of-care embolotherapy techniques ever done. This global trial including centers from North America, South America, Europe, and Australia will strengthen the level of evidence for treatment guidelines by prospectively evaluating benefit, toxicities, and quality of life after embolotherapy for NETs."